Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.
Journal
Annals of clinical and translational neurology
ISSN: 2328-9503
Titre abrégé: Ann Clin Transl Neurol
Pays: United States
ID NLM: 101623278
Informations de publication
Date de publication:
12 2019
12 2019
Historique:
received:
31
08
2019
revised:
01
10
2019
accepted:
09
10
2019
pubmed:
5
11
2019
medline:
2
10
2020
entrez:
5
11
2019
Statut:
ppublish
Résumé
Allelic variants of genes encoding for the Fc gamma receptors IIIA and IIA have been associated with the clinical response to cell-depleting antibodies in lymphoma patients. Here, we tested the hypothesis that FCGR3A and FCGR2A high-affinity polymorphisms predict clinical outcomes to alemtuzumab therapy in 85 patients with relapsing-remitting multiple sclerosis. No differences in clinical and MRI-based efficacy parameters, the development of severe infusion-associated reactions and secondary autoimmune diseases during a 2 year follow-up was observed based on FCGR3A or FCGR2A polymorphisms. This study does not support the use of FCGR genetic variants to predict clinical outcomes to alemtuzumab.
Identifiants
pubmed: 31682087
doi: 10.1002/acn3.50935
pmc: PMC6917309
doi:
Substances chimiques
FCGR2A protein, human
0
FCGR3A protein, human
0
Immunologic Factors
0
Receptors, IgG
0
Alemtuzumab
3A189DH42V
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2586-2594Subventions
Organisme : Swiss National Foundation
ID : 31003A-169664
Pays : International
Organisme : Novartis Foundation for Medical-Biological Research
Pays : International
Organisme : Sassella Foundation
Pays : International
Organisme : Hartmann Müller Foundation
Pays : International
Organisme : Olga Mayenfisch Foundation
Pays : International
Organisme : Swiss Multiple Sclerosis Society
Pays : International
Organisme : German Ministry of Education, Science, Research and Technology
ID : 01GI1603D
Pays : International
Organisme : German Ministry of Education, Science, Research and Technology
ID : FKZ01FI1603A
Pays : International
Organisme : Genzyme Therapeutics Ltd.
Pays : International
Informations de copyright
© 2019 The Authors. Annals of Clinical and Translational Neurology published by Wiley Periodicals, Inc on behalf of American Neurological Association.
Références
Neurology. 2017 Sep 12;89(11):1107-1116
pubmed: 28835401
Nat Med. 2000 Apr;6(4):443-6
pubmed: 10742152
PLoS One. 2012;7(6):e39416
pubmed: 22761788
Immunology. 2018 Jun;154(2):253-260
pubmed: 29247512
Blood. 2012 Sep 27;120(13):2650-7
pubmed: 22885164
J Clin Oncol. 2003 Nov 1;21(21):3940-7
pubmed: 12975461
Blood. 2004 Mar 15;103(6):2027-31
pubmed: 14630811
Blood. 2006 Oct 15;108(8):2720-5
pubmed: 16609067
Blood. 2002 Feb 1;99(3):754-8
pubmed: 11806974
J Clin Oncol. 2008 Apr 10;26(11):1789-96
pubmed: 18347005
Cancer Res. 2004 Jul 1;64(13):4664-9
pubmed: 15231679
Immunology. 2009 Oct;128(2):260-70
pubmed: 19740383
Int J Mol Sci. 2015 Jul 20;16(7):16414-39
pubmed: 26204829
J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):208-15
pubmed: 24849515
Ann Hematol. 2016 Sep;95(9):1483-90
pubmed: 27431582
PLoS One. 2014 Dec 26;9(12):e115920
pubmed: 25541968
Cancer Res. 2003 Oct 1;63(19):6453-7
pubmed: 14559836